Awakn Life Sciences Corp. (AWKNF)
| Previous Close | 0.1374 |
| Open | 0.1380 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's Range | 0.1350 - 0.1380 |
| 52 Week Range | 0.0422 - 0.3600 |
| Volume | |
| Avg. Volume | 14,119 |
| Market Cap | 5.874M |
| Beta (5Y Monthly) | 2.74 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.2000 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
NewsfileAwakn Life Sciences Announces Closing of Tranche of Private Placement
Toronto, Ontario--(Newsfile Corp. - April 17, 2024) - Awakn Life Sciences Corp. (CSE: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn" or the "Company") a clinical-stage biotechnology company developing medication-assisted treatments for addiction with a near-term focus on Alcohol Use Disorder (AUD), is pleased to announce that, further to its press release dated April 3, 2024, it has closed a first tranche (the "First Tranche") of its previously announced non-brokered private placement (the "Offering")
- Market Exclusive
Weekly Roundup on the Cannabis Sector & Psychedelic Sector
Key Takeaways; Cannabis Sector Canopy Growth received ISS recommendation for creation of exchangeable shares. Trulieve to hold first quarter 2024 results conference call at the beginning of May. Goodness Growth announced sale of Vireo Health of New York in effort to address financial constraints. Avant Brands entered German market through IM Cannabis deal. Key Takeaways; […]
NewsfileAwakn Life Sciences Announces Launch of Licensing Partnership Agreement with Oklahoma Based Clinic
Awakn also announces Private Placement Toronto, Ontario--(Newsfile Corp. - April 3, 2024) - Awakn Life Sciences Corp. (CSE: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn" or the "Company") a clinical-stage biotechnology company developing medication-assisted treatments for addiction with a near-term focus on Alcohol Use Disorder (AUD), announces today the launch of an additional Licensing Partnership agreement in North America. The agreement is with Rivus Wellness and Research Institute ("Rivus"), bas
